
Yet Another Value Podcast
Broyhill Asset Management's Chris Pavese on $AVTR, pick and shovel play for life sciences
Mar 21, 2024
Exploring Avantor as a key player in life sciences sector, discussing VWR acquisition and embeddedness in lab solutions, dissecting healthcare industry post-pandemic, and comparing AVTR with Thermo Fisher & Danaher for investment choices and risk assessment
01:08:52
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- AVTR focuses on self-improvement & cost-saving initiatives for sustained growth.
- AVTR's strategic acquisitions in high-growth bio-pharma market strengthen its competitive edge.
Deep dives
Implications of the Pandemic on the Life Sciences Industry
The global pandemic in 2020 significantly impacted the life sciences industry. It led to a surge in vaccine testing and development, a speculative venture frenzy into bio-pharma, and a temporary increase in demand for scientific tools and consumables which was further magnified by supply chain issues. This period of inflated demand reversed as supply chains normalized, leading to struggles in forecasting, negative earnings revisions, and challenges in returning to pre-pandemic levels.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.